cobas® TaqScreen DPX Test

Real-time discrimination of B19V and HAV in one assay

Image of cobas® TaqScreen DPX test for the detection of parvovirus B19 and HAV in laboratory tests.
Increasing the safety of human plasma and plasma products

The cobas® TaqScreen DPX Test a real-time polymerase chain reaction (PCR) assay that detects parvovirus B19 (B19V) and hepatitis A virus (HAV) in human plasma.

Features and Benefits
  • Simultaneously quantifies B19V DNA and detects HAV RNA in real time
  • Detects B19V genotypes 1, 2 and 3 and HAV genotypes I, II, III
  • Available as a B19V DNA-only quantitative assay or a dual/result B19V DNA titer and a HAV RNA reactive/non-reactive
  • Ready-to-use reagents that do not require freezing
Markedly reduce the risk of transfusion transmission

Designed to run on the cobas s 201 system, the cobas® TaqScreen DPX Test can help manage the B19V burden in plasma pools and identify HAV-contaminated units while increasing processing efficiency.


Intended use

Intended use

The cobas® TaqScreen DPX Test, for use on the cobas s 201 system, is an in vitro nucleic acid amplification test for the direct quantitation of human parvovirus B19 (B19V) DNA (genotypes 1, 2, and 3) and the direct qualitative detection of hepatitis A virus (HAV) RNA (genotypes I, II, and III) in human plasma.

This test has been submitted to the FDA as a Master File and will not have a regulatory classification.